Trial Profile
A Phase II, multicenter and open-label study of ONO-4538 in patients with pancreatic cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Sep 2022
Price :
$35
*
At a glance
- Drugs Fluorouracil (Primary) ; Irinotecan (Primary) ; Levofolinic acid (Primary) ; Nivolumab (Primary) ; Oxaliplatin (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Ono Pharmaceutical
- 13 Sep 2022 Status changed from active, no longer recruiting to completed.
- 14 Jun 2022 Planned End Date changed from 30 Jun 2022 to 31 Mar 2023.
- 01 Mar 2022 Status changed from recruiting to active, no longer recruiting.